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Summary
Objective: Leprosy post-exposure prophylaxis with single-dose rifampicin (SDR-
PEP) has proven effective and feasible, and is recommended by WHO since 2018.
This SDR-PEP toolkit was developed through the experience of the leprosy post-
exposure prophylaxis (LPEP) programme. It has been designed to facilitate and
standardise the implementation of contact tracing and SDR-PEP administration in
regions and countries that start the intervention.
Results: Four tools were developed, incorporating the current evidence for SDR-
PEP and the methods and learnings from the LPEP project in eight countries. (1) the
SDR-PEP policy/advocacy PowerPoint slide deck which will help to inform policy
makers about the evidence, practicalities and resources needed for SDR-PEP, (2) the
SDR-PEP field implementation training PowerPoint slide deck to be used to train
front line staff to implement contact tracing and PEP with SDR, (3) the SDR-PEP
generic field guide which can be used as a basis to create a location specific field
protocol for contact tracing and SDR-PEP serving as a reference for frontline field
staff. Finally, (4) the SDR-PEP toolkit guide, summarising the different components
of the toolkit and providing instructions on its optimal use.
Conclusion: In response to interest expressed by countries to implement contact
tracing and leprosy PEP with SDR in the light of the WHO recommendation of SDR-
PEP, this evidence-based, concrete yet flexible toolkit has been designed to serve
national leprosy programme managers and support them with the practical means to
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translate policy into practice. The toolkit is freely accessible on the Infolep homepages
and updated as required: https://www.leprosy-information.org/keytopic/leprosy-post-
exposure-prophylaxis-lpep-programme
Keywords: Leprosy, prophylaxis, rifampicin, single-dose, LPEP, toolkit
Introduction
Close contacts of newly diagnosed leprosy patients have an increased risk of developing
leprosy, compared to the general population.1 This risk can be substantially reduced through
the administration of a single dose of rifampicin (SDR) to contacts who meet the eligibility
criteria.2 The efficacy of a post-exposure prophylaxis (PEP) intervention has been
demonstrated in various studies,3 most notably the cluster randomised controlled COLEP
trial in Bangladesh.4,5 The Leprosy Post-Exposure Prophylaxis (LPEP) programme has
established feasibility, acceptability and impact of the intervention, under routine conditions,
across different health systems, socio-cultural settings and epidemiological conditions in
8 countries in Africa, Asia and Latin America.6,7 Of note, the LPEP programme was based on
a flexible approach tailored to local conditions to maximise acceptance and impact. Central
tenets were integration into the health care system in general and into the leprosy control
programme routine in particular, to avoid the creation of parallel and project-specific
structures and to facilitate sustainability.
Based on the current evidence, the Word Health Organization (WHO) recommends “the
use of single-dose rifampicin as preventive treatment for adult and child (2 years of age and
above) contacts of leprosy patients, after excluding leprosy and tuberculosis (TB) disease and
in the absence of other contraindications. This intervention shall be implemented by
programmes that can ensure: (i) adequate management of contacts and (ii) consent of the
index case to disclose his/her disease”.8 Unfortunately, the Operational Manual of the Global
Leprosy Strategy 2016–2020 does not contain detailed advice on the operationalisation of
leprosy prevention through PEP with SDR.9 However, Chapter 3.2: “Early case detection
through active case-finding and contact management” provides guidance on contact tracing
and screening, which is arguably the most time- and resource-intensive component of leprosy
PEP with SDR interventions. The same chapter also provides detailed advice on interventions
to increase detection of leprosy patients, stratified by epidemiological setting.
Several national leprosy programmes participating in the LPEP programme have
embraced leprosy PEP with SDR and are in the process of integrating the activity into their
national leprosy control and elimination strategies, or have already done so. Based on the
WHO recommendation and growing evidence from the field, it is anticipated that additional
countries will follow them over the coming years. The Global Partnership for Zero Leprosy
(GPLZ, https://zeroleprosy.org/) is also taking keen interest in the approach, and both the
Research Agenda and Operational Excellence working groups have dedicated subgroups
focusing on various aspects of the intervention. Similarly, ILEP (https://www.ilepfederation.
org/) is committed to continuously supporting leprosy PEP with SDR.
Based on the above, the LPEP Steering Committee found it timely to produce a set of
tools and guidance material for the introduction, implementation and documentation of
leprosy PEP with SDR. The materials are generic yet practical and form a toolkit from which
users may freely select the most relevant documentation for them. The toolkit’s primary focus
is on the needs of the national programme managers. Below we summarise the process used
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to develop and validate the toolkit, describe its individual components, and provide a link to
the permanent repository where the toolkit files are stored free of charge and can be accessed
and downloaded.
Materials and methods
The following components were developed and are featured in the toolkit:
1. SDR-PEP policy/advocacy PowerPoint slide deck.
2. SDR-PEP field implementation training PowerPoint slide deck.
3. SDR-PEP generic field guide.
4. SDR-PEP toolkit guide.
These toolkit components were developed based on documents established and validated
during the LPEP programme implementation. The main sources were the LPEP country field
guides that had been developed from the generic LPEP protocol,6 and presentations used at
the in-country launch events and for training of field-level staff. All documents were critically
reviewed in the light of the practical experience gained after 3 years of implementation in
8 different countries.7 The guiding principle, in the development of the toolkit components,
was that they should be evidence-based, concrete yet flexible, to cover a range of different
settings, and precise yet generic to facilitate adaptation to different needs and contexts. As
a result, the documents only recommend current standard practices and follow a logical
planning and temporal sequence of events.
Colour coding is used to guide the user during the adaption of the tools, as follows:
Standard text is in black while colour coding is used in the toolkit to represent sections that
will vary between settings (see Table 1).
Throughout the documents, generic terms are intentionally used to offer the chance to
adapt to local standards (e.g. “district” might be synonymous with “province” or “county” in
some settings). Similarly, the naming of health workforce functions varies between countries
(e.g. community health worker, village health volunteer, paramedical worker), as does the
allocation of tasks between different functions (e.g. what might be the responsibility of a
nurse in one country might be that of a community health worker in another system).
The toolkit documents also feature only basic formatting and are unprotected to facilitate
adaptation to national standards and integration into the corporate design of the user. Pictures
and graphs may be inserted throughout the documentation to illustrate points of relevance
Table 1. Colour coding of text passages
Text colour Adaptations to be done
Green Represents a defined number of options among which the relevant one must be selected in
accordance to the target area
Blue Indicates that a term or number must be inserted that can only be determined with reference to the
target area
Purple Identifies optional items that are applicable only to certain situations or operational purposes and
can otherwise be deleted
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customised to regional activities. The toolkit components can be used in their entirety,
independently or be selected as excerpts.
Experts with solid experience in the actual implementation of the LPEP programme
drafted all tools. Full drafts were widely shared for additional inputs and validation, by
stakeholders with links to the LPEP programme, including ILEP representatives, GPZL
working group members and national programme managers not previously involved in
LPEP programme implementation. The consultation was facilitated by Novartis Foundation
and the GPZL. Feedback was readily integrated into the drafts before finalisation of the
documents.
Results
POLICY/ADVOCACY
The SDR-PEP policy/advocacy PowerPoint contains standard background information
targeted to ministry-level staff, policy makers and donors. The presentation covers the
historic and current trends in leprosy epidemiology (globally and in the targeted
country/area), highlighting the value for a new approach to reduce annual new case
detection rates and new child patients. It also describes the current practice and tools used to
diagnose and treat leprosy at the health facility level. Contact tracing and chemoprophylaxis
are then introduced as two possible instruments to increase early case detection and reduce
the risk of contacts to develop clinical leprosy, possibly contributing to transmission
reduction. The basic approach of SDR-PEP is presented, as well as the general results of the
LPEP programme7 and the minimal essential data needs.10 Aspects regarding the rifampicin
supply chain are included, and available data on costs and cost-effectiveness of SDR-PEP are
shared. The WHO endorsement of SDR-PEP for leprosy control is featured8 and an outlook
is given on current studies that will provide complementary evidence in the field of
chemoprophylaxis.
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Figure 1. Activity flow of SDR-PEP.
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FIELD IMPLEMENTATION TRAINING GUIDE
The SDR-PEP field implementation training PowerPoint provides a set of generic slides
which can easily be adapted and then customised as a training module for the health
staff involved in leprosy PEP field activities. It includes the following key components:
First, selection criteria to facilitate the identification of intervention areas. Then, an activity
flow of SDR-PEP describes the various tasks (Figure 1), from the index patient identification
and inclusion/exclusion considerations, over contact tracing and inclusion/exclusion criteria,
SDR administration and side effects information/monitoring, and recording and reporting,
a minimal essential data form to record data on index patients and contacts are presented.10
In addition, suggested reporting and rifampicin logistics pathways are described. Finally, a
standard team composition, and the key tasks of each team member are summarised.
FIELD GUIDE
The SDR-PEP generic field guide offers assistance in the planning and implementation of
SDR-PEP by providing a template protocol for SDR-PEP. It can also serve as a reference for
frontline field staff. The guide contains a concise background on contact tracing and SDR-
PEP, and lists all standard parameters, such as logistics and resources, that need to be
considered in the implementation of the approach. It further summarises the roles and
responsibilities of the different key personnel, and describes the key steps of index patient
enrolment, contact tracing and screening for signs of leprosy, necessary referral decisions
based on the suspicion for leprosy and TB, screening for SDR eligibility, and administration
of SDR. Data recording and reporting are also presented.
TOOLKIT GUIDE
The SDR-PEP toolkit guide provides advice on the use and application of the different above
mentioned toolkit instruments. It provides a more extensive summary of the current evidence
on leprosy post-exposure prophylaxis (e.g. efficacy, safety and feasibility), summarises the
development and validation process the tools went through, and introduces the different tools.
It concludes with guidance on the adaptation of the generic documents to concrete settings on
the ground where SDR-PEP is planned to be introduced.
The documents are permanently posted on the following website: https://www.leprosy-
information.org/keytopic/leprosy-post-exposure-prophylaxis-lpep-programme.
For further guidance see https://zeroleprosy.org/. The documents can be freely
downloaded, modified and used as required as long as users correctly acknowledge the
source of the documents. Users are advised to confirm any modifications with recognized
experts in the field to ensure appropriateness in the local context.
Discussion
In response to the WHO recommendation of SDR-PEP, this toolkit intends to serve national
leprosy programme managers with the practical means to translate policy into practice.
Available experience suggests that while contact tracing and screening represent the biggest
share of work related to leprosy PEP, the SDR administration is the most contentious part of
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the intervention and often requires careful and coordinated communication and training.
Close supervision and continuous quality control are also important, and their collective
feedback may provide further indications as to the need for guidance revision.
The introduction and implementation of SDR-PEP into the routine of national leprosy
programmes will identify additional needs for tools and guidance. Together, they will form the
basis for updating the toolkit components as new experiences and insights emerge. Furthermore,
there are a number of studies currently ongoing or scheduled to start soon, that are exploring
different aspects related to chemo- and immunoprophylaxis for leprosy prevention and M. leprae
transmission interruption. Their common goal is to improve the effectiveness and impact of the
intervention, and together they are expected to provide important further evidence that will need
to be integrated into the SDR-PEP toolkit for it to remain relevant. Among these studies, we
highlight the following ones: the PEOPLE trial (2018–2022) implemented on the Comoros and
in Madagascar, which aims to define the optimal target population for leprosy PEP, including the
deployment of a single double-dose of rifampicin (SDDR; https://clinicaltrials.gov/ct2/show/
NCT03662022). The PEP4LEP trial (2018–2022) in Ethiopia, Mozambique and Tanzania
evaluates different approaches for contact tracing such as community skin camps or health
centre-based screening (https://nlrinternational.org/what-we-do/projects/pep4lep/). It also
explores the value of the SkinApp (https://leprosyrelief.org/skinapp) to facilitate early detection
and diagnosis. Furthermore, several trials assess the combination of SDR-PEP with BCG
(Maltalep in Bangladesh; 2013–201911), and multi-dose regimens of enhanced preventive
treatment (PEPþþ in Brazil, India and Indonesia; 2017–2023) for seropositive contacts while
others receive standard SDR (https://nlrinternational.org/news/pep-an-enhanced-regimen-for-
leprosy/). Trials of immunotherapeutic and immunoprophylactic vaccines (LepVax, MIP) are
also ongoing or planned in Brazil and India.12,13
Corrections, suggested modifications and additions should be communicated to the
corresponding author. Updated versions may be posted from time to time on the websites
hosting the toolkit. Each revision will be identified by consecutive version numbers.
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